(VIANEWS) - Eaton Corporation (ETN), Vertex Pharmaceuticals (VRTX), NMI Holdings (NMIH) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Eaton Corporation (ETN)
11% sales growth and 14.53% return on equity
Eaton Corporation plc is a global power management company. Electrical Americas and Electrical Global segments of Eaton Corporation plc provide electrical components, electrical distribution and assemblies and residential products. They also offer single- and three-phase power quality and connectivity products. Wiring devices, circuit protection, utility power distribution product products and power reliability equipment. The Aerospace segment includes pumps, motors hydraulic power units and hoses. It also offers electro-hydraulic pumps. Its Vehicle segment includes transmissions, controls and fuel vapor parts for vehicle manufacturers. The company's eMobility section offers voltage inverters and converters as well as onboard chargers, circuit protector units, vehicle controls, power distribution, fuel tank isolation, valves for commercial vehicles, and hybrid system components. Eaton Corporation plc was established in 1911 in Dublin, Ireland.
Earnings Per Share
As for profitability, Eaton Corporation has a trailing twelve months EPS of $3.49.
PE Ratio
Eaton Corporation has a trailing twelve months price to earnings ratio of 45.31. Meaning, the purchaser of the share is investing $45.31 for every dollar of annual earnings.
The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 14.53%.Revenue growth
The year-on-year revenue growth fell by 0.1%. We now have 19.78B in the 12 trailing months.
Sales Growth
Eaton Corporation's sales growth for the next quarter is 11%.
Volume
Today's last reported volume for Eaton Corporation is 771292 which is 60.72% below its average volume of 1963660.
Dividend Yield
According to Morningstar, Inc., the next dividend payment is on Nov 8, 2022, the estimated forward annual dividend rate is 3.24 and the estimated forward annual dividend yield is 2.22%.
2. Vertex Pharmaceuticals (VRTX)
9.7% sales growth and 30.24% return on equity
Vertex Pharmaceuticals Incorporated is a biotechnology firm that develops and markets therapies to treat cystic fibrosis. SYMDEKO/SYMKEVI and ORKAMBI are available to patients suffering from cystic fibrosis. TRIKAFTA is for patients 6 and older with CF who possess at least one F508del mutation. VX-864 is being developed for AAT deficiency treatment and is currently in Phase 2. Clinical trial. VX147 is for treatment of APOL1 mediated focal segmental glomerulosclerosis (or FSGS) and other severe kidney disease. VX-880 is for treatment of Type 1 Diabetes and is currently in Phase 1/2 clinical trials. VX-548 is a NaV1.8 inhibitor that treats acute, neuropathic and musculoskeletal pain and is now in Phase 3. Clinical trial. It sells products to specialty pharmacies, specialty distributors, retail chains and hospitals around the world. Affinia Therapeutics, Inc., Arbor Biotechnologies, Inc., and CRISPR Therapeutics AG are some of its collaborations. ; Kymera Therapeutics, Inc., Mammoth Biosciences, Inc., Moderna, Inc., Obsidian Therapeutics, Inc., Skyhawk Therapeutics, Inc., Ribometrix, Inc., Genomics plc, Merck KGaA, Darmstadt, Germany, as well as X-Chem, Inc. Vertex Pharmacs Incorporated was established in Boston, Massachusetts in 1989.
Earnings Per Share
As for profitability, Vertex Pharmaceuticals has a trailing twelve months EPS of $10.49.
PE Ratio
Vertex Pharmaceuticals has a trailing twelve months price to earnings ratio of 29.77. Meaning, the purchaser of the share is investing $29.77 for every dollar of annual earnings.
The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 30.24%.Previous days news about Vertex Pharmaceuticals(VRTX)
- According to MarketWatch on Thursday, 8 December, "Shares of Entrada Therapeutics Inc. rallied 15% in premarket trading on Thursday after the company announced a deal with Vertex Pharmaceuticals Inc. that aims to develop treatments for myotonic dystrophy type 1, a genetic disorder that causes progressive muscle weakness. "
3. NMI Holdings (NMIH)
8.9% sales growth and 18.44% return on equity
Through its subsidiaries, NMI Holdings, Inc. provides private mortgage guarantee insurance services in the United States. It offers outsourced loan reviews and mortgage insurance to loan originators. The company serves banks and credit unions in the United States, as well as national and regional banks and money centers. It also provides loan review services to mortgage originators. Emeryville is the headquarters of this company, which was founded in 2011.
Earnings per Share
NMI Holdings' trailing 12 months profit per share was $3.2.
PE Ratio
NMI Holdings' trailing 12-month price-earnings ratio is 6.58. The purchaser of the shares is investing $6.58 per dollar in annual earnings.
For the 12 trailing months, the company's return-on-equity, which is a measure of the business' profitability relative to shareholders' equity, was 18.44%.Revenue growth
The year-on-year revenue growth was 5.3%. It now stands at 515.31M in the 12 trailing months.
Sales Growth
NMI Holdings saw a 8.2% increase in sales for its current quarter, and an 8.9% rise for its next.
Yearly Top and Bottom Value
NMI Holdings's stock is valued at $21.05 at 15:22 EST, way below its 52-week high of $27.25 and way above its 52-week low of $15.33.
4. Stryker Corp (SYK)
7.3% sales growth and 14.1% return on equity
Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies. The MedSurg and Neurotechnology segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical device products that are used in various medical specialties. This segment also provides neurotechnology products, which include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke; and craniomaxillofacial implant products, including cranial, maxillofacial, and chest wall devices, as well as dural substitutes and sealants. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.
Earnings Per Share
As for profitability, Stryker Corp has a trailing twelve months EPS of $3.69.
PE Ratio
Stryker Corp has a trailing twelve months price to earnings ratio of 66.61. Meaning, the purchaser of the share is investing $66.61 for every dollar of annual earnings.
The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 14.1%.Dividend Yield
Morningstar, Inc. has stated that the next dividend payment will be on Sep 28, 2022. The forward dividend rate for 2020 is estimated at 2.78, and the forward dividend yield is estimated to be 1.22%.